|
|
- Spencer T, Wilens T, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Therapeutics. 2006;266-279.
- National Institute of Mental Health. Attention Deficit Hyperactivity Disorder. Bethesda (MD): National Institute of Mental Health, National Institutes of Health, US Department of Health and Human Services; 2003. NIH Publication Number: NIH 3572.
- Barkley RA, Fischer M, Smallish L, et al. Young adult outcomes of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry. 2006;45(2):192-202.
- Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention deficit/hyperactivity disorder reduces risk for substance abuse disorder. Pediatrics. 1999;104(2)e20.
- Liebson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention deficit/hyperactivity disorder. JAMA. 2001;285:60-66.
- Biederman J, Faraone SV, Keenan K, et al. Family-genetic and psychosocial risk factors in DSM-III attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1990;29(4):526-533.
- ADDERALL XR [package insert], Shire US, Inc. 2004.
- Goodman D, Ginsberg L, Weisler R, et al. An interim analysis of quality of life, effectiveness, safety, tolerability (QU.E.S.T) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrums. 2005;26-34.
- American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. 4th ed. Washington, DC; American Psychiatric Association: 1994.
- American Academy of Pediatrics. Clinical practice guidelines: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158-70.
- Biederman J, Faraone SV. The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives. Psychiatr Clin North Am. 2004;27(2):225-32.
- Elia J. Attention deficit/hyperactivity disorder: pharmacotherapy. Psychiatry. 2005;2:27-35.
- Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Att Dis. 2005;9(1):275-289.
- Tulloch SJ, Zhang Y, McLean A, et al. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy. 2002;22(11):1405-1415.
- Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SL1381 (Adderall XR) in children with attention deficit/hyperactivity disorder. Pediatrics. 2002;110(2 Pt 1):258-266.
|
|
 |
|
| |
|
